Dyslipidemia Archives - Page 2 of 32 - Endocrinology Advisor


Alirocumab May Have Greater CV Reduction Benefit in Patients With Diabetes

After an acute coronary syndrome event, alirocumab may offer greater risk reductions for future cardiovascular events in patients with diabetes vs those without diabetes, according to study results published in The Lancet Diabetes & Endocrinology. In the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; ClinicalTrials.gov Identifier:…

Next post in Diabetes